Argon inhalation attenuates systemic inflammation and rescues lung architecture during experimental neonatal sepsis
link.springer.com shows its articles on its own site.
Read the article on link.springer.com ↗Article · Dec 2023 · 1 min read
In brief
In brief
This preclinical study demonstrates that argon inhalation (70% Ar/30% O2) significantly improves survival and reduces systemic inflammation in a neonatal mouse sepsis model. The therapy attenuates cytokine release and preserves lung architecture, suggesting potential as an adjunct treatment for mechanically ventilated septic neonates.
Written by the GCMD Library team from the article.
Abstract
Purpose
Neonatal sepsis is a systemic inflammatory infection common in premature infants and a leading cause of mortality. Argon is an emerging interest in the field of noble gas therapy. Neonates with severe sepsis are frequently mechanically ventilated creating an opportunity for inhalation therapy. We aimed to investigate argon inhalation as a novel experimental therapy in neonatal sepsis.
Methods
Sepsis was established in C57BL/6 neonatal mice by a lipopolysaccharide intraperitoneal injection on postnatal day 9. Septic pup mice were exposed to room air as well as non-septic controls. In the argon group, septic pup mice were exposed to argon (70% Ar, 30% O2) for 6 h in a temperature-controlled environment.
Results
At 6 h, survival was significantly enhanced when septic mice received argon compared to septic controls. Serum profiles of cytokine release were significantly attenuated as well as lung architecture restored.
Conclusions
Our findings suggest that argon inhalation as a novel treatment for neonatal sepsis, reducing mortality and counteracting the acute systemic inflammatory response in the blood and preserving the architecture of the lung. This research can contribute to a paradigm shift in the treatment and outcome of neonates with sepsis.